Risk factors of long term symptoms and outcomes among patients discharged after covid-19: prospective, multicentre observational study.
COVID-19
Critical care
Journal
BMJ medicine
ISSN: 2754-0413
Titre abrégé: BMJ Med
Pays: England
ID NLM: 9918487584306676
Informations de publication
Date de publication:
2022
2022
Historique:
received:
14
12
2021
accepted:
10
05
2022
entrez:
20
3
2023
pubmed:
21
3
2023
medline:
21
3
2023
Statut:
epublish
Résumé
To investigate risk factors and subphenotypes associated with long term symptoms and outcomes after hospital admission for covid-19. Prospective, multicentre observational study. 93 hospitals in France. Data from 2187 adults admitted to hospital with covid-19 in France between 1 February 2020 and 30 June 2021. Primary endpoint was the total number of persistent symptoms at six months after hospital admission that were not present before admission. Outcomes examined at six months were persistent symptoms, Hospital Anxiety and Depression Scale, six minute walk test distances, 36-Item Short Form Health Survey scores, and ability to resume previous professional activities and self-care. Secondary endpoints included vital status at six months, and results of standardised quality-of-life scores. Additionally, an unsupervised consensus clustering algorithm was used to identify subphenotypes based on the severity of hospital course received by patients. 1109 (50.7%) of 2187 participants had at least one persistent symptom. Factors associated with an increased number of persistent symptoms were in-hospital supplemental oxygen (odds ratio 1.12, 95% confidence interval 1 to 1.24), no intensive care unit admission (1.15, 1.01 to 1.32), female sex (1.33, 1.22 to 1.45), gastrointestinal haemorrhage (1.51, 1.02 to 2.23), a thromboembolic event (1.66, 1.17 to 2.34), and congestive heart failure (1.76, 1.27 to 2.43). Three subphenotypes were identified: including patients with the least severe hospital course (based on ventilatory support requirements). Although Hospital Anxiety and Depression Scale scores were within normal values for all groups, patients of intermediate severity and more comorbidities had a higher median Hospital Anxiety and Depression Scale score than did the other subphenotypes. Patients in the subphenotype with most severe hospital course had worse short form-36 scores and were less able to resume their professional activity or care for themselves as before compared with other subphenotypes. Persistent symptoms after hospital admission were frequent, regardless of acute covid-19 severity. However, patients in more severe subphenotypes had a significantly worse functional status and were less likely to resume their professional activity or able to take care of themselves as before. NCT04262921.
Identifiants
pubmed: 36936553
doi: 10.1136/bmjmed-2021-000093
pii: bmjmed-2021-000093
pmc: PMC9951375
doi:
Banques de données
ClinicalTrials.gov
['NCT04262921']
Types de publication
Journal Article
Langues
eng
Pagination
e000093Informations de copyright
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/disclosure-of-interest/ and declare: support from REACTing (REsearch & ACtion emergING infectious diseases) consortium and by a grant of the French Ministry of Health (PHRC n°20–0424) for the submitted work; JG reports personal fees from Merck, grants and personal fees from ViiV healthcare, grants and personal fees from Gilead Sciences, personal fees from Roche, personal fees from AstraZeneca, and personal fees from Janssen outside of the submitted work; other authors declare no competing interests.
Références
JAMA Intern Med. 2022 Jan 1;182(1):19-25
pubmed: 34747982
PLoS One. 2020 Nov 9;15(11):e0240784
pubmed: 33166287
Lancet. 2021 Dec 4;398(10316):2057-2059
pubmed: 34774190
JAMA. 2021 Apr 20;325(15):1525-1534
pubmed: 33729425
BMC Med. 2021 May 20;19(1):129
pubmed: 34011359
N Engl J Med. 2021 Aug 12;385(7):577-579
pubmed: 34192429
JAMA. 2020 Aug 11;324(6):603-605
pubmed: 32644129
BMC Infect Dis. 2021 Feb 10;21(1):169
pubmed: 33568097
Lancet Reg Health Eur. 2021 Jul;6:100122
pubmed: 34027514
Lancet Reg Health Eur. 2021 Sep;8:100186
pubmed: 34386785
Clin Exp Allergy. 2021 Sep;51(9):1107-1120
pubmed: 34351016
Lancet Respir Med. 2021 Aug;9(8):812-814
pubmed: 34273267
Clin Microbiol Infect. 2022 Apr;28(4):611.e9-611.e16
pubmed: 34763058
Clin Microbiol Infect. 2021 Jul;27(7):1041.e1-1041.e4
pubmed: 34125067
Lancet Respir Med. 2021 Jun;9(6):570-572
pubmed: 33587889
Lancet Respir Med. 2021 Dec;9(12):1467-1478
pubmed: 34416191
Lancet. 2021 Aug 28;398(10302):747-758
pubmed: 34454673
BMJ. 2021 Jul 26;374:n1648
pubmed: 34312178
Clin Microbiol Infect. 2021 Aug;27(8):1151-1157
pubmed: 33901667
J Gen Intern Med. 2021 Dec;36(12):3772-3777
pubmed: 34355349
Lancet Respir Med. 2021 Nov;9(11):1275-1287
pubmed: 34627560
JAMA Netw Open. 2021 Feb 1;4(2):e210830
pubmed: 33606031
Clin Infect Dis. 2022 Jan 29;74(2):301-308
pubmed: 33893486